These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23813092)

  • 41. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.
    Hoenigl M; Duettmann W; Raggam RB; Seeber K; Troppan K; Fruhwald S; Prueller F; Wagner J; Valentin T; Zollner-Schwetz I; Wölfler A; Krause R
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3262-7. PubMed ID: 23629724
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
    Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
    J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retrospective serological tests for determining the optimal blood concentration of voriconazole for treating fungal infection.
    Okuda T; Okuda A; Watanabe N; Takao M; Takayanagi K
    Yakugaku Zasshi; 2008 Dec; 128(12):1811-8. PubMed ID: 19043301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Invasive pulmonary infection due to Trichoderma longibrachiatum mimicking invasive Aspergillosis in a neutropenic patient successfully treated with voriconazole combined with caspofungin.
    Alanio A; Brethon B; Feuilhade de Chauvin M; de Kerviler E; Leblanc T; Lacroix C; Baruchel A; Menotti J
    Clin Infect Dis; 2008 May; 46(10):e116-8. PubMed ID: 18419477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multicenter phase 2 study of empirical low-dose liposomal amphotericin B in patients with refractory febrile neutropenia.
    Miyao K; Sawa M; Kurata M; Suzuki R; Sakemura R; Sakai T; Kato T; Sahashi S; Tsushita N; Ozawa Y; Tsuzuki M; Kohno A; Adachi T; Watanabe K; Ohbayashi K; Inagaki Y; Atsuta Y; Emi N
    Int J Hematol; 2017 Jan; 105(1):79-86. PubMed ID: 27696283
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utility of serum galactomannan antigen testing combined with chest computed tomography for early diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies with febrile neutropenia after antifungal drug treatment.
    Wang X; Guo G; Cai R; He P; Zhang M
    J Int Med Res; 2019 Feb; 47(2):783-790. PubMed ID: 30477369
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Voriconazole in the treatment of invasive fungal infections.
    Keady S; Thacker M
    Intensive Crit Care Nurs; 2005 Dec; 21(6):370-3. PubMed ID: 15985371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
    Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
    J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients.
    Imataki O; Yamaguchi K; Uemura M; Fukuoka N
    Transpl Infect Dis; 2018 Aug; 20(4):e12886. PubMed ID: 29570914
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Micafungin for empirical antifungal therapy in patients with febrile neutropenia: multicenter phase 2 study.
    Mizuno H; Sawa M; Yanada M; Shirahata M; Watanabe M; Kato T; Nagai H; Ozawa Y; Morishita T; Tsuzuki M; Goto E; Tsujimura A; Suzuki R; Atsuta Y; Emi N; Naoe T
    Int J Hematol; 2013 Aug; 98(2):231-6. PubMed ID: 23857638
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
    Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan.
    Saito T; Fujiuchi S; Tao Y; Sasaki Y; Ogawa K; Suzuki K; Tada A; Kuba M; Kato T; Kawabata M; Kurashima A; Sakatani M;
    Infection; 2012 Dec; 40(6):661-7. PubMed ID: 22956473
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
    Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
    Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.
    den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD
    J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antifungal prophylaxis in haematology patients: the role of voriconazole.
    Hicheri Y; Cook G; Cordonnier C
    Clin Microbiol Infect; 2012 Apr; 18 Suppl 2():1-15. PubMed ID: 22409648
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of itraconazole as empirical antifungal therapy in febrile neutropenic patients with hematologic malignancies: an open-lable, multicenter, observational trial in a Chinese cohort.
    Cheng S; Zhou JF; Zou P; Huang XJ; Jin J; Shen ZX
    Chin Med J (Engl); 2011 Nov; 124(22):3670-5. PubMed ID: 22340222
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
    Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecht R; Thiel E; Haas A; Ruhnke M; Lode H
    Clin Infect Dis; 2002 Mar; 34(5):563-71. PubMed ID: 11807679
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.
    Fournier S; Pavageau W; Feuillhade M; Deplus S; Zagdanski AM; Verola O; Dombret H; Molina JM
    Eur J Clin Microbiol Infect Dis; 2002 Dec; 21(12):892-6. PubMed ID: 12525928
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy.
    Baden LR; Katz JT; Fishman JA; Koziol C; DelVecchio A; Doran M; Rubin RH
    Transplantation; 2003 Dec; 76(11):1632-7. PubMed ID: 14702539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.